agilon health, inc. (AGL) is a Westerville, Ohio-based healthcare services company that partners with primary care physician groups to manage full-risk, capitated care for Medicare patients through its Total Care Model. The stock was trading at $103.88 shortly after 10:10 a.m. ET on Wednesday, down $11.32, or 9.83%, from the prior session's close of $115.20. The direction of the move is unambiguously lower, and it marks the stock's sharpest intraday decline since September. No verified news release, regulatory filing, or analyst action published in the session explains the pullback, leaving positioning and profit-taking after a parabolic rally as the most plausible drivers.
No verified news or fundamental catalyst found for Wednesday's retreat. The most recent company event was Tuesday afternoon's virtual investor presentation, "Driving Performance At Scale: The agilon Framework," featuring the chief medical officer, interim chief technology officer and chief business operations officer. The materials covered clinical pathways, the technology and data platform, physician engagement and quality programs, with operating metrics dated Dec. 31, 2025 — approximately 30 markets, roughly 2,200 primary care physicians, more than 500,000 Medicare patients and about $6 billion of managed total medical expense. Notably, the event offered no update to 2026 guidance, no preliminary 2027 outlook and no new financial targets. Shares slipped 1.33% during Tuesday's regular session, so the current leg lower is more consistent with delayed "sell-the-news" behavior than with a fresh disclosure.
The more defensible explanation is technical. AGL had climbed from $86.63 on Nov. 2 to $116.75 on Nov. 16, a gain of about 35% in ten sessions, including back-to-back advances of 9.61% on Nov. 4 and 18.23% on Nov. 5. After a move of that magnitude, a 10% giveback is a routine mean-reversion event rather than an information event. The stock's exceptionally thin float and wide quoted spreads mean relatively modest sell orders can move the tape by several percentage points; individual one-minute prints in the hundreds of shares were common on Wednesday morning. That combination — an extended share price, a small float and a shallow order book — is consistent with speculative, momentum-driven trading rather than institutional distribution.
Turnover in the first hour ran at a pace roughly in line with, rather than far above, the stock's three-month average of about 216,000 shares, which argues against a large institutional exit. No sector-wide catalyst was identified: a decline of this size in a single small-cap name is far larger than what a broad healthcare or equity-market move would account for, pointing to company- and positioning-specific factors.
Technically, the stock broke below Tuesday's low of $110.02 and the $112 area that had contained trading for most of the prior two weeks, triggering momentum-driven selling. It remains well above its 50-day moving average near $91.87 and its 200-day average around $70.09, so the medium-term uptrend is intact despite the sharp intraday damage. The 52-week range of $7.48 to $133.04 underscores how far the shares have traveled and how much profit is available to be taken.
The score runs from 0, meaning no meaningful news and a move that is entirely normal for the stock, to 100, meaning transformative news combined with an extreme and rare price move. AGL earns 26 out of 100.
On the news side, the verified inputs were weak: an investor education event with no financial guidance, no contract announcement and no analyst revision — routine content for a company of this size, and barely material relative to a roughly $1.7 billion market capitalization. The price behavior was more notable than the news. Wednesday's 9.83% decline was about four times the stock's average absolute daily move of 2.5% across the last 69 sessions, and only two sessions in that window produced a larger swing. Strong price behavior paired with weak news produces a below-midpoint score.
agilon health reports fourth-quarter and full-year 2026 results in late February, and investors will focus on medical margin, per-member cost trends and any early read on 2027 Medicare Advantage bids. Consensus estimates point to a full-year loss per share with a return to profitability projected for 2027, so the durability of that swing is the central question. Sector developments matter enormously here: changes to Medicare Advantage reimbursement, risk-adjustment coding rules and inpatient utilization patterns feed directly into the company's capitated economics. Analyst sentiment remains mixed, with a consensus Hold rating and a wide dispersion of targets. Risks include rising specialty drug costs, unfavorable prior-year development, heavy customer concentration in a handful of markets, and the stock's own volatility, with a beta above 3 and a history of double-digit single-session swings.
Tickeron's Trending AI Robots page curates the strongest-performing automated strategies under current market conditions from a library of hundreds of AI trading bots covering thousands of tickers. Because bots differ widely by strategy, timeframe, performance metrics and traded symbols, the trending list offers a useful, continuously refreshed snapshot of where systematic capital is finding traction. Explore the page to compare approaches and see which bots are leading the pack right now.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The Moving Average Convergence Divergence (MACD) for AGL turned positive on November 04, 2026. Looking at past instances where AGL's MACD turned positive, the stock continued to rise in 39 of 45 cases over the following month. The odds of a continued upward trend are 87%.
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on AGL as a result. In 64 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
AGL moved above its 50-day moving average on November 03, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for AGL crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 77%.
Following a +5.85% 3-day Advance, the price is estimated to grow further. Considering data from situations where AGL advanced for three days, in 232 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The Aroon Indicator entered an Uptrend today. In 155 of 183 cases where AGL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.
The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AGL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
AGL broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Valuation Rating of 21 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.368) is normal, around the industry mean (204.532). P/E Ratio (-8.013) is within average values for comparable stocks, (21.572). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.154) among similar stocks. P/S Ratio (0.253) is also within normal values, averaging (2.688).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. AGL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 37 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AGL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry HospitalNursingManagement